NCT01093534View on ClinicalTrials.gov

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

PHASE4CompletedINTERVENTIONAL
Enrollment

547

Participants

Timeline

Start Date

January 19, 2010

Primary Completion Date

June 23, 2011

Study Completion Date

June 23, 2011

Conditions
Detrusor OveractivityOveractive Bladder
Interventions
DRUG

Placebo

Matching solifenacin placebo tablet

DRUG

solifenacin

Tablet for oral administration

Trial Locations (79)

1082

Budapest

1115

Budapest

1431

Sofia

1606

Sofia

2650

Edegem

3004

Drammen

3103

Tønsberg

4020

Linz

4809

Arendal

5507

Haugesund

6725

Szeged

8000

Székesfehérvár

8500

Kortrijk

9000

Ghent

9010

Varba

10115

Berlin

11530

New York

12601

New York

13285

Marseille

14186

Stockholm

19611

West Reading

20132

Milan

20153

Milan

21100

Varese

22185

Lund

28031

Madrid

28046

Madrid

28905

Madrid

30625

Hanover

31096

Haifa

34664

Istanbul

41380

Kocaeli

49100

Petah Tikva

52074

Aachen

52621

Ramat Gan

75970

Paris

81679

Munich

83100

Avellino

101000

Moscow

105425

Moscow

115516

Moscow

117815

Moscow

117997

Moscow

119435

Moscow

123836

Moscow

125206

Moscow

197089

Saint Peterburg

199044

Saint Peterburg

300376

Timișoara

603018

Nizhny Novgorod

A-8036

Graz

A-4020

Linz

V8T 5G1

Victoria

V8V 3N1

Victoria

L4M 7G1

Barrie

L6T 4S5

Brampton

N3R 4N3

Brantford

N2N 2B9

Kitchener

M4N 3M5

Toronto

J1H 5N4

Sherbrooke

625 00

Brno

500 05

Hradec Králové

147 00

Podolí

00133

Rome

85-094

Bydgoszcz

31-530

Krakow

00-846

Warsaw

01-432

Warsaw

02-005

Warsaw

02-929

Warsaw

Unknown

Yaroslavl

085 01

Bardejov

036 59

Martin

010 01

Žilina

08036

Barcelona

06018

Ankara

HA1 3JU

Harrow

SE5 9RS

London

W2 2YP

London

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT01093534 - Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. | Biotech Hunter | Biotech Hunter